Publications by authors named "Lindsay Rosen"
Article Synopsis
- * A study involving 290 patients using acalabrutinib revealed 8 cases of VAs over 1063 person-years, with a significantly higher incidence rate compared to non-BTKi-treated patients.
- * The findings imply that ventricular arrhythmias could be a common side effect of all BTK inhibitors, with no specific heart-related factors (besides age) found to predict these events.
Background: Post-market analyses revealed unanticipated links between first-generation Bruton's tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel selective second (next)-generation BTKi therapy, acalabrutinib, is unknown.
Methods: Leveraging a large cohort of consecutive B cell cancer patients treated with acalabrutinib from 2014 to 2020, we assessed the incidence and ramifications of new or worsened hypertension [systolic blood pressure (SBP) ≥ 130 mmHg] after acalabrutinib initiation.